Ipilimumab for the treatment of metastatic prostate cancer

Concetta Alaia, Mariarosaria Boccellino, Silvia Zappavigna, Evzen Amler, Lucio Quagliuolo, Sabrina Rossetti, Gaetano Facchini, Michele Caraglia

Research output: Contribution to journalArticlepeer-review


Introduction: Immunotherapy with checkpoint inhibitors is beginning to be recognized as a valid weapon for the treatment of metastatic prostate cancer (PCa) when chemotherapy fails. Ipilimumab (ipi) is a fully humanized monoclonal antibody that blocks the activity of CTLA4. It also has a molecular weight of 148 kDa and is water-soluble at physiological pH. Ipi was first approved by the FDA for the treatment of malignant melanoma and is currently being studied in metastatic castration-resistant prostate cancer, with promising early results. Areas covered: The aim of this review is to collate the most significant preclinical and clinical studies available that look at ipi to propose new strategies for the future. Expert opinion: Additional studies are required to reduce toxicity and increase the activity of ipi in PCa. A possible strategy is to combine ipi with standard anti-cancer therapeutics such as vaccines, PDL1 inhibitors, antiandrogen drugs, and chemotherapy agents. Several initial results have suggested that combination strategies are useful to increase the activity in mCRPC, even if the toxicity of the treatment can increase. The activity of combined treatments is still not predictable, but considering the ongoing studies, we believe that they have good potential that will lead to the discovery of an optimal therapeutic strategy.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalExpert Opinion on Biological Therapy
Publication statusPublished - 2018


  • chemotherapy
  • circulating tumour cells
  • immunotherapy
  • ipilimumab
  • Metastatic prostate cancer
  • microRNA
  • PDL1 inhibitors
  • vaccines

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Ipilimumab for the treatment of metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this